This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stuart L. Nightingale, MD
Food and Drug Administration Rockville, Md

JAMA. 1997;278(16):1317.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Jelsema is correct in stating that 2 strategies are presented by the CDC for the prevention of early onset GBS disease, one that includes culturing for the organism, and the other that addresses treatment based on maternal risk. However, as indicated by its title, the FDA article dealt only with matters regarding the detection of the GBS organism, either by an antigen test or by culturing the organism. The agency's goal with this FDA Safety Alert was to educate those who may use the GBS antigen tests to the limitations of the tests. The alert was not written as a general discussion on the prevention of early onset GBS disease. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?